at the very least, one-tailed testing should be disclosed wherever it is used; for example, when the hypothesis of the study is defined, in the assumptions for the sample size estimation, and in the post hoc testing criteria.
None of these occurred in this paper (1) .
In addition, as sample size estimation becomes more commonplace in clinical research, it is important that all of the assumptions used are disclosed to the readers. In addition to specifying the LY and 0 values, the effect size must be clearly defined (3). In their paper (11, the authors used a 33% decrease in "transfusions" between tranexamic acid and placebo as the minimal desired effect size. However, this criterion may be interpreted in at least two ways: 1) an arithmetic difference of 33% in the transfusion rate between the two groups (i.e., from 66% to 33%) or a fractional difference of 33% (i.e., a difference of 66% X 33% 
